CJD (Creutzfeldt-Jakob disease) drug success "opens doors for diagnostic test":
This article was originally published in Clinica
The unexpected success of a one-off, highly experimental trial of a drug to halt the progress of Creutzfeldt-Jakob disease (CJD) in a UK patient has "opened the doors to developing a diagnostic test". So said doctors at a meeting held last week in Belfast, Northern Ireland, to discuss the developments. Although more research is needed to confirm the effectiveness of pentosan polysulphate (PPS) in halting or even reversing the neurodegenerative effects of the disease, experts agree that the earliest possible diagnosis is the key to preventing its slow but invariably fatal progression.
You may also be interested in...
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.